Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
University of Chicago
mi
from
Chicago, IL
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Cooper Health System
mi
from
Franklin Twp, NJ
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Cooper Health System
mi
from
Franklin Twp, NJ
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Ohio Health Research Institute / Riverside Methodist Hospital
mi
from
Columbus, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Ohio Health Research Institute / Riverside Methodist Hospital
mi
from
Columbus, OH
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
A Phase I Study Of Pelvic Radiation Therapy With Concomitant Cisplatin And Weekly Topotecan (IND# 58,13) Chemotherapy In Patients With Cervical Carcinoma And Paraortic Nodal Metastasis As The Only Evidence Of Extrapelvic Disease
Status: Archived
Updated: 1/1/1970
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Christiana Care Health Systems
mi
from
Newark, DE
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Christiana Care Health Systems
mi
from
Newark, DE
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
St Louis Children's Hospital
mi
from
St Louis, MO
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
St Louis Children's Hospital
mi
from
St Louis, MO
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
FirstHealth Moore Regional Hospital
mi
from
Pinehurst, NC
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
FirstHealth Moore Regional Hospital
mi
from
Pinehurst, NC
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Sanford USD Medical Center
mi
from
Sioux Falls, SD
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Sanford USD Medical Center
mi
from
Sioux Falls, SD
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
US Army Institute of Surgical Research
mi
from
Ft Sam Houston, TX
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
US Army Institute of Surgical Research
mi
from
Ft Sam Houston, TX
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Carilion Gynecologic Oncology Associates
mi
from
Roanoke, VA
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3)
Status: Archived
Updated: 1/1/1970
Carilion Gynecologic Oncology Associates
mi
from
Roanoke, VA
Collecting Endometrial and Ovarian Tissues Samples From Patients Without Cancer Undergoing a Hysterectomy
Pilot Study of Benign Endometrial and Ovarian Tissues
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Collecting Endometrial and Ovarian Tissues Samples From Patients Without Cancer Undergoing a Hysterectomy
Pilot Study of Benign Endometrial and Ovarian Tissues
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Collecting Endometrial and Ovarian Tissues Samples From Patients Without Cancer Undergoing a Hysterectomy
Pilot Study of Benign Endometrial and Ovarian Tissues
Status: Archived
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Collecting Endometrial and Ovarian Tissues Samples From Patients Without Cancer Undergoing a Hysterectomy
Pilot Study of Benign Endometrial and Ovarian Tissues
Status: Archived
Updated: 1/1/1970
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Molokai General Hospital
mi
from
Kaunakakai, HI
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Updated: 1/1/1970
Molokai General Hospital
mi
from
Kaunakakai, HI
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memoral Sloan Kettering Cancer Center at Phelps
mi
from
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memoral Sloan Kettering Cancer Center at Phelps
mi
from
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Pegaptanib Therapy in Uveitis
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Pegaptanib Therapy in Uveitis
Evaluation of the Utility of Intravitreal Vascular Endothelial Growth Factor (VEGF) Blockade With Pegaptanib in Cystoid Macular Edema (CME) Associated With Non Infectious Intermediate and Panuveitis in an Open Label, Non Randomized, Uncontrolled Interventional Pilot Trial.
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids
Status: Archived
John Moran Eye Center
mi
from
Salt Lake City, UT
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids
Status: Archived
Updated: 1/1/1970
John Moran Eye Center
mi
from
Salt Lake City, UT
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Apremilast in the Treatment of Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
Apremilast in the Treatment of Uveitis
An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia
Status: Archived
Northwestern University
mi
from
Chicago, IL
Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt
Status: Archived
Wills Eye Institute
mi
from
Philadelphia, PA
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt
Status: Archived
Updated: 1/1/1970
Wills Eye Institute
mi
from
Philadelphia, PA
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine
mi
from
Miami, FL
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine
mi
from
Miami, FL
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
OU Cancer Institute
mi
from
Oklahoma, OK
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
OU Cancer Institute
mi
from
Oklahoma, OK
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
Updated: 1/1/1970
Department of Ophthalmology, Mount Sinai School of Medicine
mi
from
New York, NY
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN